Photo-ID Architects, Schidler Bulfesh Architecture, Studio Verkade, WGE-Brands, and The Smith Group.
And the following were nominated by community members to be included in the book:
Jodidio Correa, The Smith Group, Saskatoon
Charles de Goede, JDS Architects, Saskatoon
Diana Leopold, Studio Verkade, Saskatoon
Mark Pirie, The Smith Group, Saskatoon
Kelsey Williamson, The Smith Group, Saskatoon
The book was edited by J.V. Nieuwenhuizen, and was released in June 2016.
References
Category:2016 non-fiction books
Category:Canadian non-fiction books
Category:Geography books
Category:Environmental non-fiction books, and the other survived the surgery as well. One of the patients underwent surgery for relapse. The patient with extranodal SLL died of relapse within 2 years after R-CHOP therapy.
When using R-CHOP for the first-line treatment of DLBCL patients, one of the major considerations is the significant recovery of peripheral blood cell count. There were several studies on post-transplant lymphoproliferative disease (PTLD) patients who were treated with R-CHOP. Most patients received only 4 cycles of chemotherapy after receiving reduced-dose conditioning and bone marrow or stem cell transplantation. The overall 2-year survival rate was approximately 80%, and the 5-year survival rate was approximately 70% ([@B6], [@B13]). Our 3-year survival rate was approximately 60%, with one patient remaining alive for more than 5 years after R-CHOP therapy. However, there is no large scale study comparing post-transplant patients and non-transplant patients. Further investigation is needed to clarify the post-transplant survival of DLBCL patients.
After R-CHOP therapy, DLBCL patients usually receive Rituximab maintenance therapy. In our study, all of the DLBCL patients with complete remission achieved 5-year disease-free survival. These results were in accordance with previous reports ([@B14], [@B15]). In the case of CD20 negativity, the 5-year disease-free survival rate was less than 50%. This result is similar to previous reports, and many authors have reported that disease progression occurs in patients with CD20 negativity in the central
Related links:
Comments